If desire and physical comfort with intimacy have quietly changed since menopause, you are not imagining it — and wanting closeness at 56 or 58 is not something to feel embarrassed about. What matters is understanding what actually shifts hormonally, and why a thoughtful conversation about testosterone in women looks very different from the one men have.
Desire after menopause is a real, physiological topic — not a personal failing
Menopause brings a decline in estrogen and, more gradually, in circulating testosterone. Both changes can affect sexual desire, arousal, and the comfort of the vaginal tissue itself. The distress some women feel about a persistent drop in desire even has a clinical name — hypoactive sexual desire disorder (HSDD) — which the medical community recognizes as legitimate and worth addressing [1].
That recognition matters. For years, women were told that fading desire was simply "part of aging" and left without options or context. Current guidance from professional societies treats low desire as a genuine concern that deserves a careful, individualized evaluation — not a shrug [1][2].
It's also worth separating two things that often travel together: desire (the psychological and hormonal pull toward intimacy) and comfort (the physical tissue changes of the genitourinary syndrome of menopause). They have different drivers and different tools, which is exactly why a provider asks detailed questions rather than reaching for one answer.
Why the testosterone conversation is different for women
Men and women both make testosterone, but the scale, the purpose, and the monitoring are not the same. In men, evaluation and treatment of low testosterone follow well-established protocols with clear reference ranges and specific safety monitoring — including checks on red blood cell counts and prostate markers, and, when fertility is a concern, semen analysis, because exogenous testosterone can suppress sperm production [3].
None of that framework transfers to a woman after menopause. There is no semen analysis in this conversation, no prostate to monitor, and the goal is not to restore a "male" range. Instead, an independent provider considering testosterone for a post-menopausal woman is thinking about *physiologic* levels — the small amounts a woman's body would naturally make — and about desire specifically.
A widely cited international consensus statement concluded that the only evidence-based indication for testosterone therapy in women is HSDD, and only after other contributing factors are addressed. It also emphasized that there is no clearly defined blood level that predicts response, and that treatment should not push a woman's levels above the normal premenopausal range [2].
Source: [2] Global Consensus Position Statement on the Use of Testosterone Therapy for Women
What markers a provider actually watches in women
Because total testosterone alone tells an incomplete story in women, a provider typically looks at the fuller picture:
- Total testosterone — the overall circulating amount. In women this is a fraction of male levels, so labs must use assays sensitive enough to measure it accurately [2].
- Sex hormone–binding globulin (SHBG) — a protein that binds testosterone and keeps it inactive. When SHBG is high, less testosterone is biologically available even if the total looks "normal" [2].
- Free (or calculated free) testosterone — an estimate of the fraction not bound to SHBG, which is the portion that can act on tissue.
The consensus guidance is that testosterone in women should not be started to correct a number, but rather considered for the *symptom* of distressing low desire — with blood levels used mainly to confirm that a woman stays within the normal premenopausal range and to avoid excess [2]. That is a meaningfully different philosophy from the target-driven approach used in men.
Importantly, professional guidance does not support prescribing testosterone for cognition, energy, bone, or general well-being in women, because the evidence for those uses isn't established [2]. So while brain fog, fatigue, and sleep are real and worth a full menopause conversation, testosterone is not the tool aimed at them — a distinction a good provider will make clearly.
relative level · marker = Monitoring goal
Source: [2] Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Where estrogen, local therapy, and non-hormonal tools fit
Testosterone is only one item on a longer list. For the physical comfort side — dryness, irritation, discomfort with intimacy — providers often discuss local vaginal estrogen or non-hormonal moisturizers, which act on tissue rather than desire [4]. For broader menopause symptoms like hot flashes and disrupted sleep, systemic hormone therapy is a separate discussion with its own evidence base and its own timing considerations [4][5].
On the old fear-based headlines: the medical understanding has evolved considerably since the early 2000s. Major societies now emphasize that for many healthy women who begin therapy within roughly ten years of menopause or before age 60, the benefit-risk profile is generally more favorable than the blanket warnings of the past suggested — and that decisions should be individualized rather than driven by fear [5]. It is a real conversation to have with a provider, not a closed door.
And desire itself is rarely one-dimensional. Relationship dynamics, stress, sleep, medications, mood, and physical comfort all feed into it. A thorough provider treats testosterone as one possible tool among several — not the whole answer.
A note on compounded testosterone for women
There is currently no testosterone product approved by the FDA specifically for use in women; products on the market are approved for men [2]. This is one reason some providers discuss compounded formulations. If compounding comes up, understand this clearly:
*Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.*
Guidance also cautions against compounded or "pellet" formulations that can deliver unpredictably high levels, which is exactly what careful monitoring aims to avoid [2]. A prescription is never guaranteed; whether any therapy is appropriate is a decision made by an independent licensed provider after evaluating you individually.
What a first conversation tends to cover
A provider will usually ask about the nature and duration of the change, whether physical comfort or desire (or both) shifted, your relationship and stress context, current medications, and your overall health history. Baseline labs — including total testosterone, SHBG, and calculated free testosterone — help complete the picture. From there, any plan is built around your goals and monitored over time.
This article is educational and is not medical advice. It cannot diagnose you or tell you what to take; only an independent licensed provider can do that.
Source: [2] Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Where Velri fits
Velri is a technology and coordination company — not a medical practice. We help make the process less intimidating: coordinating baseline lab work, connecting you with an independent, licensed provider group for a private evaluation, and — *only if that provider determines it's appropriate and writes a prescription* — coordinating with an independent, licensed pharmacy for fulfillment. Velri does not provide medical care, does not prescribe, and never guarantees a particular treatment. The goal is simply to give a smart, curious adult a calm, judgment-free path to current, balanced answers.
